南京鼓楼医院呼吸与危重症医学科行政副主任，主任医师，教授，博士研究生导师。美国科罗拉多大学医学院国立犹太健康医院（National Jewish Health）和伊利诺伊大学芝加哥分校访问学者。任中华医学会呼吸病学分会间质病学组副组长、中华医学会呼吸病学分会青年委员会委员（第九、第十届）。江苏省第五期“333”工程和南京市“十三五”青年卫生工程人才。长期从事间质性肺病、肺纤维化及呼吸罕见病的临床诊治和基础研究。以第一及通讯作者在Am J Resp Crit Care Med、J Control Release、Clin Transl Med、Respirology等杂志发表SCI论著30余篇。执笔撰写和参与10余部有关间质性肺病和肺纤维化相关中国专家共识及指南，研究成果被2026年国际特发性肺纤维化急性加重指南引用。先后多次在美国呼吸年会、欧洲呼吸病年会、中华医学会呼吸分会年会、中国医师会呼吸医师分会等国际国内进行大会专题报告。主持国家自然科学基金项目4项、省市院级课题7项、参编教材及专著8部，并获批国家发明专利及江苏省卫健委新技术引进一等奖。

1.     中华医学会呼吸病学分会间质病学组副组长

2.     中华医学会呼吸病学分会青年委员会委员（第九、十届）

3.     中国医师协会呼吸医师分会呼吸影像学组委员

4.     中国抗癌协会肿瘤呼吸病学专委会常委

5.     中国老年医学会呼吸医师分委员

6.     中国康复医学会呼吸康复委员会危重症康复学组委员

7.     中国罕见病联盟呼吸病学分会委员

8.  江苏省医学会呼吸病学分会委员

1.     1. Huang X, Zhang Y, Yan X, Huang Q, Chen M, Jiang C, Wang Z , Sun D, Li Y, Ding J , Qiu X, Cao M  (Corresponding author), Xiao Y. Integrin/CD44-targeted liposomes remodel the pulmonary microenvironment to alleviate acute exacerbation of pulmonary fibrosis. J Control Release. 2026 Jan 10:389:114427. (IF：12.39‌).

2.     2. Gu P, Wang D, Zhang J, Wang X, Chen Z, Gu L, Liu M, Meng F, Yang J, Cai H, Xiao Y, Chen Y, Cao M (Corresponding author). Protective function of Interleukin-22 in pulmonary fibrosis. Clin Transl Med. 2021 Aug;11(8):e509. (IF: 11.492）

3.     3. Cao M, Cai H, Ding J, Zhuang Y, Wang Z. Bronchial varices in congenital unilateral pulmonary vein atresia. Am J Resp Crit Care Med. 2013;187:1267-1268. (IF：24.7）

4.     4. Zhao Y, Shi Y, Zhang J, Zhang H, Wang Z, Wu S, Zhang M, Liu M, Ye X, Gu H, Jiang C, Ye X, Zhu H, Li Q, Huang X, Cao M (Corresponding author). The potential lipid biomarker 5-HETE for acute exacerbation identified by metabolomics in patients with idiopathic pulmonary fibrosis. Respirology. 2025 Feb; 30(2): 158-167.  (IF 6.6)。

5.    5. Zhu H, Chen M, Li Q, Cui S, Jiang C, Ye X, Hou Sh, Zhang J, HuangX, Cao M (Corresponding author). Identification and validation of the protective gene BCAT2 related to amino acid metabolism in idiopathic pulmonary fibrosis. Clin Exp Med. 2026 Feb 10;26(1):145.(IF：4.49)。

6.    6. Long S, Ma S, Chu C, Zhang Y, Zhao W, Li Z, Cao Y, Huang S, Yang J, Rosas IO, Cao M (Corresponding author), Yu G, Wang L. Autophagy induced by glycosylated CD147 attenuates fibroblast activation and myofibroblast differentiation. J Biol Chem. 2026 Jul 28;302(9):113374. (IF 4.1)

7.     7. Ye X, Zhang M, Liu M, Zhu H, Ye X, Jiang C, Li Q, Huang X, Cao M (Corresponding author). Comparative study on mouse models of acute exacerbation of pulmonary fibrosis. Exp Ther Med. 2026 Jul 24;32(4):253. (IF 2.2)

8.     8. Jiang C, Cui S, Hou S, Chen M, Huang Q, Zhang X, Li S, Yang D, Cao M (Corresponding author). Long-term radiologic trajectories and corticosteroid strategies in COVID-19 patients with pre-existing ILD: a 24-month cohort study. BMC Pulm Med. 2026 Feb 10;26(1):117.  (IF 3.10).

9.     9. Zhao Y, Li Q, Zhu H, Jiang C, Chen M, Ye X, Hou S, Cui S, Huang X, Cao M (Corresponding author). Berberine Ameliorates Pulmonary Fibrosis via Downregulating the TGFBR2-Mediated Signaling. Chem Biol Drug Des. 2026 Mar;107(3):e70264. (IF 3.30).

10.  10. Huang X, Si W, Zhao Y, Ye X, Gu H, Zhang M, Wu S, Shi Y, Xiao Y, Cao M (Corresponding author). Novel 3D-based deep learning for classification of acute exacerbation of idiopathic pulmonary fibrosis using high-resolution CT.  BMJ Open Respir Res. 2024. Mar, 11: e002226. (IF 4.1)。

11.  Wu S, Liu M, Zhang M, Ye X, Gu H, Jiang C, Zhu H, Ye X, Li Q, Huang X, Cao M (Corresponding author). The gene expression of CALD1, CDH2, and POSTN in fibroblast are related to idiopathic pulmonary fibrosis. Front Immunol. 2024 Feb 2:15:1275064. (IF 7.3)。

12.  Ye X, Zhang M, Gu H, Liu M, Zhao Y, Shi Y, Wu S, Jiang C, Ye X, Zhu H, Li Q, Huang X, Cao M (Corresponding author). Animal models of acute exacerbation of pulmonary fibrosis. Respir Res. 2023 Nov 25;24(1):296. (IF 5.8)。

13.  Huang X, Cao M (Corresponding author), Xiao Y. Alveolar macrophages in pulmonary alveolar proteinosis: origin, function, and therapeutic strategies. Front Immunol. 2023 Jun 14:14:1195988. (IF 7.3)。

14.  Cao M, Gu L, Guo L, Liu M, Wang T, Zhang J, Zhang H, Zhang Y, Shi Y, Zhao Y, Qiu X, Gui X, Ma M, Tian Y, Liu X, Meng F, Xiao Y, Sun L. Elevated Expression of Growth Differentiation Factor-15 Is Associated With Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Front Immunol. 2022 Jun 15;13:891448. (IF: 8.786).

15.  Zhang Y, Gu L, Xia Q, Tian L, Qi J, Cao M (Corresponding author). Radix Astragali and Radix Angelicae Sinensis in the Treatment of Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-analysis. Front Pharmacol. 2020 Apr 30;11:415. (IF:5.81)

16.  Yu-Feng Zhang, Li-Na Gu, Jia Qi, Qing-Qing Xia, Li-Jun Tian, Wei-Long Jiang, Meng-Shu Cao (Corresponding author). Construction of potential idiopathic pulmonary fibrosis related microRNA and messenger RNA regulatory network. Chin Med J (Engl). 2021 Jan 5;134(5):584-586. (IF:6.133)

17.  Mengshu Cao (Corresponding author), Jian Sheng, Xiaohua Qiu, Dandan Wang, Dongmei Wang, Yang Wang, Yonglong Xiao and Hourong Cai. Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study. BMC Pulmonary Medicine. 2019;19(3):215. (IF:3.317)

18.  Mengshu-Cao (Corresponding author), Jian Sheng, Tian-Zhen Wang, Xiao-Hua Qiu, Dong-Mei Wang, Yang Wang, Yong-Long Xiao, Hou-Rong Cai. Acute exacerbation of idiopathic pulmonary fibrosis: usual interstitial pneumonitis vs. possible usual interstitial pneumonitis pattern. Chin Med J (Engl).2019;132(18):2177-2184. (IF:6.13)

19.  Xianhua Gui, XiaohuaQiu, Miaomiao Xie, Yaqiong Tian, Cao Min, Mei Huang, Wu Hongyan, Tingting Chen, Xin Zhang, Jingyu Chen, Mengshu Cao (Corresponding author), Hourong Cai. Prognostic Value of Serum Osteopontinin Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Biomed Res Int. 2020 Feb 10;2020:3424208.(IF:3.411)

20.  Cao M (Corresponding author),Sheng J, Wang TZ, Qiu XH, Wang DM, Wang Y, Xiao YL, Cai HR. Acute exacerbation of idiopathic pulmonary fibrosis: usual interstitial pneumonitis vs. possible usual interstitial pneumonitis pattern. Chin Med J (Engl). 2019;132(18):2177-2184. ( IF:6.13)

21.  Yu M, Guo Y, Zhang P, Xue J, Yang J, Cai Q, You X; Ma J, Yang D, Jia Y, Wang Y, Chi S, and Cao M (Corresponding author), Chen J, Liu X. Increased circulating Wnt5a protein in patients with rheumatoid arthritis-associated interstitial pneumonia (RA-ILD). Immunobiology. 2019 Apr 30. 224 (4):551-559. (IF: 3.144)

22.  Zhang Y, Jiang W, Xia Q, Qi J, Cao M (Corresponding author). Pharmacological mechanism of Astragalus and Angelica in the treatment of idiopathic pulmonary fibrosis based on network pharmacology. European Journal of Integrative Medicine. 2019;32101003.(IF:2.5)

23.  Lu J, Ma M, Zhao Q, Meng F, Wang D, Cai H, Cao M (Corresponding author). The Clinical Characteristics and Outcomes of Follicular Bronchiolitis in Chinese Adult Patients. Sci Rep. 2018;8:7300. （IF: 4.6）

24.  Cao M, Swigris JJ, Wang X, Cao M, Qiu Y, Huang M, Xiao Y, Cai H. Plasma Leptin is Elevated in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Mediators Inflamm. 2016;2016:6940480.（IF：4.711）.

25. Chen Zhiyong, Cao Mengshu (Co-author), Plana Maria Nieves, Liang Jun, Cai Hourong, Kuwana Masataka, Sun Lingyun. Utility of anti-MDA5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care& Research. 2013;65: 1316-1324. (IF：4.851)17.

26. Cao MS, Cai HR, Zhang YW, Meng FQ, Sun LY. Organizing pneumonia associated with common variable immunodeficiency. Chin Med J (Engl). 2012 Sep;125(17):3195-7. (IF: 6.133)

27. 中华医学会呼吸病学分会间质病学组，中国医师协会呼吸医师分会间质性肺疾病工作委员会（主执笔人：曹孟淑，蔡后荣，代华平）。特发性肺纤维化急性加重诊断和治疗中国专家共识。中华医学杂志，2019;99(26): 2014-2023。

1.     国家自然科学基金面上项目，“GDF-15通过驱动LOX-5/5-HETE脂代谢失调在IPF急性加重发病中的作用研究”。项目编号：82570105，2026.1-2029.12。49万元，主持。

2.     南京鼓楼医院临床研究专项面上项目，大剂量糖皮质激素冲击治疗特发性肺纤维化急性加重的前瞻性、单中心、随机对照研究。项目编号：2022-LCYJ-MS-11. 2022.7-2025.6，50万元，主持。

3.     国家自然科学基金面上项目，“白介素22通过JAK2/STAT3抑制TGF-βR2表达参与特发性肺纤维化发病机制研究”。项目编号：82070064，2021.1-2024.12。55万元，主持。

4.     江苏省第五期“333工程”第三层次人才培养工程项目：瘦素对特发性肺纤维化急性加重的病情监测及预后价值研究。2020.01-2021.12，5万元，主持。

5.     国家自然科学基金面上项目，“Leptin调控PPARγ/NF-κB参与IPF急性加重发病机制的研究”。项目编号：81670059，2017.1-2020.12，53万元，主持。

6.     国家自然科学基金青年基金项目，白介素22 调控TGF-β 信号通道对特发性肺纤维化作用机制的研究。项目编号：81200049，2013/01-2015/12，23万元，主持。

7.     江苏省第五期“333工程”第三层次人才培养工程项目，2018.01-2020.12。

8.     十三五南京市卫生青年人才培养工程（第一层次）项目资助。项目编号：QRX17005，2017.01-2020.12，主持，32万元。

9.     江苏省政府留学奖学金资助，JS-2013-060，7万元。

1. 2021年度江苏省卫健委引进新技术一等奖。特发性肺纤维化急性加重规范化诊治模式的建立与实践。第一完成人：曹孟淑。

2. 2025年获得国家发明专利。曹孟淑; 叶旭; 黄歆梅; 刘梦影; 张明蕊 ; 一种腺病毒诱导肺纤维化急性加重动物模型的建立方法, 2025-2-28, 中国, 202310907975.1 (发明专利)